Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanc ...

Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the ...

Both Johnson & JohnsonJNJ and MerckMRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 ...

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing data.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs ...